AR067997A1 - ORGANIC COMPOUNDS - Google Patents
ORGANIC COMPOUNDSInfo
- Publication number
- AR067997A1 AR067997A1 ARP080103643A ARP080103643A AR067997A1 AR 067997 A1 AR067997 A1 AR 067997A1 AR P080103643 A ARP080103643 A AR P080103643A AR P080103643 A ARP080103643 A AR P080103643A AR 067997 A1 AR067997 A1 AR 067997A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- antagonist
- agonist
- colipid
- composition
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 239000005557 antagonist Substances 0.000 abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 3
- 229940088679 drug related substance Drugs 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 abstract 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 abstract 1
- 229940123169 Caspase inhibitor Drugs 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 229940122858 Elastase inhibitor Drugs 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940125400 channel inhibitor Drugs 0.000 abstract 1
- 229960000265 cromoglicic acid Drugs 0.000 abstract 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003602 elastase inhibitor Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 abstract 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 230000000510 mucolytic effect Effects 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a una composicion farmacéutica que comprende: (A) una o más sustancias medicamentosas; (B) un lípido; (C) un colípido; y (D) un mejorador de flujo; en donde el colípido y el mejorador de flujo juntos forman una dispersion liposomal que contiene vesículas lipídicas que encapsulan la una o más sustancias medicamentosas. La composicion farmacéutica opcionalmente se seca para formar una formulacion en polvo seco que tiene flujo suelto y de preferencia es adecuada para administracion por inhalacion o nasal. También se describe un proceso para preparar la composicion y la formulacion en polvo seco. Reivindicacion 2: La composicion de conformidad con la reivindicacion 1 en donde el diámetro promedio de las vesículas lipídicas está entre 70 y 550 nm. Reivindicacion 3: La composicion de conformidad con la reivindicacion 1 o 2, en donde la o cada sustancia medicamentosa es un agonista del adrenoceptor-beta2, un antagonista muscarínico, un glucocorticosteriode, un agonista del receptor de glucocorticoides no esteroide, un agonista de A2a, un antagonista de A2b, un antihistamínico, un inhibidor de caspasa, un antagonista de LTB4, un antagonista de LTD4, un inhibidor de fosfodiesterasa, un mucolitico, un inhibidor de metaloproteinasa de matriz metálica, un antagonista del receptor de leucotrieno, una hormona del crecimiento, heparina, estradiol, un antagonista de prostaglandina D2, un antagonista del receptor de CRTH2, cromoglicato de sodio, un inhibidor de la síntesis de IgE un antibiotico, un interferon, un inhibidor del canal de potasio, un inmunomodulador, un agente citostático, un inhibidor de elastasa, un antineoplásico, un inhibidor de prostatina, un péptido, un oIigonucleotido ARN (tal como ARNic), ADN, un plásmido, insulina, una interleucina, GLP-1, un agente antineoplásico, o un anticuerpo.This refers to a pharmaceutical composition comprising: (A) one or more medicinal substances; (B) a lipid; (C) a colipid; and (D) a flow improver; wherein the colipid and the flow improver together form a liposomal dispersion containing lipid vesicles that encapsulate the one or more drug substances. The pharmaceutical composition is optionally dried to form a dry powder formulation that has loose flow and is preferably suitable for inhalation or nasal administration. A process for preparing the composition and dry powder formulation is also described. Claim 2: The composition according to claim 1 wherein the average diameter of the lipid vesicles is between 70 and 550 nm. Claim 3: The composition according to claim 1 or 2, wherein the or each drug substance is an adrenoceptor-beta2 agonist, a muscarinic antagonist, a glucocorticosteriode, a non-steroidal glucocorticoid receptor agonist, an A2a agonist, an A2b antagonist, an antihistamine, a caspase inhibitor, an LTB4 antagonist, an LTD4 antagonist, a phosphodiesterase inhibitor, a mucolytic, a metal matrix metalloproteinase inhibitor, a leukotriene receptor antagonist, a growth hormone , heparin, estradiol, a prostaglandin D2 antagonist, a CRTH2 receptor antagonist, sodium cromoglycate, an inhibitor of IgE synthesis an antibiotic, an interferon, a potassium channel inhibitor, an immunomodulator, a cytostatic agent, a elastase inhibitor, an antineoplastic, a prostatin inhibitor, a peptide, an RNA oligonucleotide (such as siRNA), DNA, a plasmid, insu lina, an interleukin, GLP-1, an antineoplastic agent, or an antibody.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114981 | 2007-08-24 | ||
| EP07123163 | 2007-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067997A1 true AR067997A1 (en) | 2009-10-28 |
Family
ID=40149638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103643A AR067997A1 (en) | 2007-08-24 | 2008-08-21 | ORGANIC COMPOUNDS |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR067997A1 (en) |
| CL (1) | CL2008002479A1 (en) |
| PE (1) | PE20090607A1 (en) |
| TW (1) | TW200916126A (en) |
| WO (1) | WO2009027337A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5508003B2 (en) | 2006-06-30 | 2014-05-28 | アイスイティカ ピーティーワイ リミテッド | Process for the preparation of biologically active compounds in nanoparticulate form |
| BRPI1014275B8 (en) | 2009-04-24 | 2021-05-25 | Iceutica Pty Ltd | composition comprising indomethacin particles dispersed in at least two partially ground mill materials |
| US8808734B2 (en) | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
| CN104394846B (en) * | 2012-05-03 | 2018-10-19 | 爱尔兰詹森科学公司 | Polyinosinic acid-polycytidylic acid (poly(I:C)) formulations for the treatment of upper respiratory infections |
| WO2018160295A1 (en) * | 2017-01-25 | 2018-09-07 | Yiannios James John | Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| JP2021512860A (en) | 2018-02-01 | 2021-05-20 | コーバス・ファーマシューティカルズ・インコーポレイテッド | Pharmaceutical product |
| US20190231783A1 (en) * | 2018-02-01 | 2019-08-01 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations |
| MX2021005508A (en) * | 2018-11-13 | 2021-09-08 | Civitas Therapeutics Inc | Respirable polynucleotide powder formulations for inhalation. |
| US10729687B1 (en) * | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US20220249678A1 (en) * | 2019-07-10 | 2022-08-11 | The University Of Hong Kong | PEGylated synthetic KL4 peptide, Compositions and Methods Thereof |
| CN114209651A (en) * | 2021-11-18 | 2022-03-22 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof |
| CN114053226A (en) * | 2021-11-18 | 2022-02-18 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefminox sodium compound and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2227989A1 (en) * | 1995-08-01 | 1997-02-13 | Karen Ophelia Hamilton | Liposomal oligonucleotide compositions |
| EP2660322A3 (en) * | 2003-04-17 | 2013-11-13 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| US20070160657A1 (en) * | 2003-08-01 | 2007-07-12 | National Institute Of Advanced Industrial Science | Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome |
| DK1771206T3 (en) * | 2004-05-05 | 2018-05-22 | Silence Therapeutics Gmbh | LIPIDS, LIPID COMPLEXES AND USE THEREOF |
| GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| AU2005326371A1 (en) * | 2005-01-28 | 2006-08-03 | Kyowa Hakko Kirin Co., Ltd. | Composition for inhibiting expression of target gene |
| US20070172430A1 (en) * | 2006-01-20 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Dry powder compositions for rna influenza therapeutics |
| WO2007121947A1 (en) * | 2006-04-20 | 2007-11-01 | Silence Therapeutics Ag. | Lipoplex formulations for specific delivery to vascular endothelium |
| GB0608838D0 (en) * | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
-
2008
- 2008-08-21 AR ARP080103643A patent/AR067997A1/en unknown
- 2008-08-22 CL CL2008002479A patent/CL2008002479A1/en unknown
- 2008-08-22 WO PCT/EP2008/061018 patent/WO2009027337A1/en not_active Ceased
- 2008-08-22 PE PE2008001429A patent/PE20090607A1/en not_active Application Discontinuation
- 2008-08-22 TW TW097132233A patent/TW200916126A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200916126A (en) | 2009-04-16 |
| PE20090607A1 (en) | 2009-06-11 |
| CL2008002479A1 (en) | 2009-05-08 |
| WO2009027337A1 (en) | 2009-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067997A1 (en) | ORGANIC COMPOUNDS | |
| US11660307B2 (en) | Methods for treating SARS CoV-2 infections | |
| AR069572A1 (en) | PHARMACEUTICAL FORMULATIONS OF PHENYLEFRINE AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION | |
| Gordaliza | Natural products as leads to anticancer drugs | |
| AR053412A1 (en) | INHIBITING COMPOUNDS OF INTERACTION BETWEEN MDM2 AND P53, A METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND TO MANUFACTURE MEDICATIONS | |
| CN110464718A (en) | Pharmaceutical composition comprising POH derivative | |
| CL2019000209A1 (en) | Novel orally administrable formulation. | |
| AR086249A1 (en) | COMPOSITIONS OF VAGINAL ADMINISTRATION FAST DISSOLUTION TABLETS | |
| WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
| CN107613768B (en) | Pharmaceutical composition comprising perillyl alcohol derivatives | |
| CO6150127A2 (en) | FLIBANSERINE FORMULATIONS AND METHOD TO MANUFACTURE THEM | |
| GT200500155A (en) | PLATINUM-RESISTANT CANCER THERAPY | |
| BRPI0818324B8 (en) | liquid formulation containing luteinizing hormone (LH) or a variant thereof, its use, its form of presentation, process for its preparation and pharmaceutical composition | |
| US20230124862A1 (en) | Bismuth thiol compounds and compositions and methods of treating microbial co-infections | |
| CL2010001275A1 (en) | Method for producing a compacted intermediate product of bibw 2992 ma2 comprising a stage of compaction by rollers of bibw 2992 ma2 or optionally in a premix with 0-1.0% lubricant in a free fall or flip mixer and a stage of sifting; compacted intermediate product; compressed. | |
| AR064826A1 (en) | FORMULATIONS OF ANTI-IL-13 ANTIBODIES AND USES OF THE SAME. DEVICES, PATCH AND SYRINGE | |
| CR9468A (en) | OBLEA CONTAINING STEROID HORMONES | |
| PE20050488A1 (en) | INDIVIDUALLY DOSED, CHEWABLE, NON-COMPRESSED FORMS OF ADMINISTRATION | |
| MXPA06011467A (en) | Active substance combination comprising a carbinol combined to at least an nsaid. | |
| UY30126A1 (en) | A NEW PHARMACEUTICALLY ACCEPTABLE SALT OF 2-HIDROXI-3- (5- (MORFOLIN-4-ILMETIL) -PIRIDIN-2-L) 1H-INDOL-5-CARBONITRILE, PROCEDURES FOR THE PREPARATION, COMPOSITIONS CONTAINING IT AND APPLICATIONS | |
| EA201070626A1 (en) | DELIVERY SYSTEM OF MEDICINES FOR THE INTRODUCTION OF WATER-SOLUBLE CATION AND AMFILA PHARMACEUTICAL ACTIVE SUBSTANCE | |
| US20070207977A1 (en) | Naphthalimide compositions and uses thereof | |
| TR200601092T1 (en) | New oral pharmaceutical formulations containing the active ingredient irbesartan. | |
| AR055953A1 (en) | SUBEROILANILIDE HYDROXAMIC ACID FORMULATIONS AND PROCEDURES FOR THE PRODUCTION OF THE SAME | |
| Kumar et al. | Synthesis, spectral characterization, antimicrobial activity and docking studies against DNA Gyrase-A of new 4-chloro-3-nitrobenzene sulfonamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |